Gu Naibing, Wang Xinlai, Di Zhengli, Xiong Jing, Ma Yue, Yan Yu'e, Qian Yihua, Zhang Quanzeng, Yu Jia
Department of Human Anatomy, Histology and Embryology, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, Xi'an 710061, China.
Department of Neurology, Xi'an Central Hospital, Xi'an Jiaotong University School of Medicine, Xi'an 710003, China.
Aging (Albany NY). 2019 Nov 26;11(22):10266-10283. doi: 10.18632/aging.102455.
OBJECTIVE: This study was conducted to elucidate the long non-coding RNA FOXD2-AS1 (lncRNA FOXD2-AS1) expression in glioma and its mechanism on the biological features of glioma cells and the drug resistance of temozolomide (TMZ). RESULTS: Highly expressed FOXD2-AS1 was found in glioma. There was more powerful chemotherapeutic resistance of TMZ resistant cell lines than that of the parent cell lines. Silence of FOXD2-AS1 suppressed proliferation and drug resistance and promoted apoptosis of drug-resistant glioma cells. Overexpressed FOXD2-AS1 presented an opposite trend. FOXD2-AS1 could be used as a competing endogenous RNA to adsorb miR-98-5p, thereby up-regulating CPEB4. CONCLUSION: Our study suggests that down-regulated FOXD2-AS1 repressed invasion, proliferation, migration and drug resistance of drug-resistant glioma cells while stimulating their apoptosis via increasing miR-98-5p and inhibiting CPEB4 expression. METHODS: FOXD2-AS1, microRNA-98-5p (miR-98-5p) and cytoplasmic polyadenylation element binding (CPEB4) expression in glioma tissues were tested. Expression of E-cadherin, N-cadherin and Vimentin in glioma cells were explored. A series of assays were conducted to detect the function of FOXD2-AS1 in migration, proliferation, apoptosis, and invasion of glioma cells. Changes in drug-resistance of cells under TMZ treatment were examined, and tumor formation in nude mice was performed to test the changes of drug resistance .
Biochem Biophys Res Commun. 2018-12-13
Aging (Albany NY). 2019-3-11
Eur Rev Med Pharmacol Sci. 2021-1
Acta Neuropathol Commun. 2025-6-5
Int J Mol Sci. 2024-10-26
J Nanobiotechnology. 2024-8-29
Discov Oncol. 2024-8-29
Mol Neurobiol. 2025-2
Technol Cancer Res Treat. 2023
Oxid Med Cell Longev. 2023
Front Endocrinol (Lausanne). 2019-4-8
Cell Mol Biol Lett. 2019-4-2
Aging (Albany NY). 2019-3-11
Biochem Biophys Res Commun. 2018-12-13